Showing results (121-130 of 190) with videos related to
Sort By:
Pageof 19
Melanoma Research|November 10, 2020
Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic targetRiyue Bao, Oliver Surriga, Daniel J Olson, et al.Cancer Discovery|July 30, 2021
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic MelanomaAntoni Ribas, Theresa Medina, John M Kirkwood, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid TumorsDiwakar Davar, Roberta Zappasodi, Hong Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2025
IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial CarcinomaDavid H Aggen, Meredith McKean, Jean H Hoffman-Censits, et al.Molecular Cancer Therapeutics|February 8, 2020
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071Sophie Piperno-Neumann, James Larkin, Richard D Carvajal, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid TumorsGeorge D Demetri, Jason J Luke, Antoine Hollebecque, et al.Journal for Immunotherapy of Cancer|June 6, 2024
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanomaJoseph J Sacco, Richard D Carvajal, Marcus O Butler, et al.Journal for Immunotherapy of Cancer|March 8, 2024
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumorsNikhil I Khushalani, Patrick A Ott, Robert L Ferris, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib StudyFunda Meric-Bernstam, Randy F Sweis, Stefan Kasper, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in MelanomaDaniel J Olson, Zeynep Eroglu, Bruce Brockstein, et al.Pageof 19